{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:10Z","timestamp":1787008990126,"version":"build-2736575974"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"6","funder":[{"name":"Genentech, Inc"},{"name":"Shionogi & Co. Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Influenza viruses harboring treatment-emergent I38F\/M\/N\/T substitutions in the polymerase acidic (PA) endonuclease exhibited reduced susceptibility to baloxavir and were associated with virus rebound and variable clinical response in clinical trials. US regulatory review of registrational trial data also identified treatment-emergent PA substitutions E23K in A\/H1N1 viruses and E23G\/K, A37T, and E199G in A\/H3N2 viruses, which conferred reduced susceptibility to baloxavir, although to a lesser degree than I38F\/M\/N\/T substitutions, and were associated with virus rebound. Although these non-I38 substitutions emerged less frequently than substitutions at I38, they represent alternate pathways to baloxavir virologic resistance and should be monitored accordingly.<\/jats:p>","DOI":"10.1093\/infdis\/jiaa164","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T15:08:52Z","timestamp":1586012932000},"page":"957-961","source":"Crossref","is-referenced-by-count":48,"title":["Treatment-Emergent Influenza Virus Polymerase Acidic Substitutions Independent of Those at I38 Associated With Reduced Baloxavir Susceptibility and Virus Rebound in Trials of Baloxavir Marboxil"],"prefix":"10.1093","volume":"222","author":[{"given":"William L","family":"Ince","sequence":"first","affiliation":[{"name":"Division of Antivirals, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraser B","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Biometrics IV, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian J","family":"O\u2019Rear","sequence":"additional","affiliation":[{"name":"Division of Antivirals, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomson","sequence":"additional","affiliation":[{"name":"Division of Antivirals, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"key":"2020081708165814400_CIT0001","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1542\/peds.80.2.275","article-title":"Children with influenza A infection: treatment with rimantadine","volume":"80","author":"Hall","year":"1987","journal-title":"Pediatrics"},{"key":"2020081708165814400_CIT0002","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/596311","article-title":"Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children","volume":"48","author":"Stephenson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020081708165814400_CIT0003","author":"FDA Review and Evaluation.","year":"2018"},{"key":"2020081708165814400_CIT0004","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"2020081708165814400_CIT0005","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci Rep"},{"key":"2020081708165814400_CIT0006","article-title":"Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes","author":"Hirotsu","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020081708165814400_CIT0007","first-page":"346","article-title":"Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza","volume":"221","author":"Uehara","year":"2020","journal-title":"J Infect Dis"},{"key":"2020081708165814400_CIT0008","author":"FDA Review and Evaluation","year":"2019"},{"key":"2020081708165814400_CIT0009","doi-asserted-by":"crossref","first-page":"1800666","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666","article-title":"Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016\/17 and 2017\/18 seasons","volume":"24","author":"Gubareva","year":"2019","journal-title":"Euro Surveill"},{"key":"2020081708165814400_CIT0010","doi-asserted-by":"crossref","first-page":"1800698","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800698","article-title":"Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018","volume":"24","author":"Takashita","year":"2019","journal-title":"Euro Surveill"},{"key":"2020081708165814400_CIT0011","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41564-019-0609-0","article-title":"Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets","volume":"5","author":"Imai","year":"2020","journal-title":"Nat Microbiol"},{"key":"2020081708165814400_CIT0012","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3201\/eid2511.190757","article-title":"Human-to-human transmission of influenza A(H3N2) virus with reduced susceptibility to Baloxavir, Japan, February 2019","volume":"25","author":"Takashita","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2020081708165814400_CIT0013","doi-asserted-by":"crossref","first-page":"1900170","DOI":"10.2807\/1560-7917.ES.2019.24.12.1900170","article-title":"Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019","volume":"24","author":"Takashita","year":"2019","journal-title":"Euro Surveill"},{"key":"2020081708165814400_CIT0014","first-page":"367","article-title":"Replicative fitness of seasonal influenza A viruses with decreased susceptibility to Baloxavir","volume":"221","author":"Chesnokov","year":"2020","journal-title":"J Infect Dis"},{"key":"2020081708165814400_CIT0015","doi-asserted-by":"crossref","first-page":"e1002830","DOI":"10.1371\/journal.ppat.1002830","article-title":"Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease","volume":"8","author":"DuBois","year":"2012","journal-title":"PLoS Pathog"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa164\/33173767\/jiaa164.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/6\/957\/33656434\/jiaa164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/6\/957\/33656434\/jiaa164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T12:40:14Z","timestamp":1666269614000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/222\/6\/957\/5816798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,4,7]]},"published-print":{"date-parts":[[2020,8,17]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa164","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9,15]]},"published":{"date-parts":[[2020,4,7]]}}}